Skip to main content

Volume 14 Supplement 1

6th International Conference on cGMP: Generators, Effectors and Therapeutic Implications

Meeting abstracts

Edited by John C Burnett Jr, Franz Hofmann, Kazuwa Nakao, Harald HHW Schmidt and Johannes-Peter Stasch

Publication of this supplement has been fully funded by Bayer Pharma AG. Johannes-Peter Stasch is an employee of Bayer Pharma AG, Wuppertal, Germany. He holds many patents on sGC stimulators and sGC activators. John C Burnett Jr is the chairman of the advisory board for Nile Therapeutics and is a Co-Founder and the Chief Scientific Officer for Zumbro Discovery. Mayo Clinic has licensed CD-NP to Nile Therapeutics and MANP to Zumbro Discovery. The other Supplement Editors declare that they have no competing interests.

6th International Conference on cGMP: Generators, Effectors and Therapeutic Implications. Go to conference site.

Erfurt, Germany28-30 June 2013

Page 3 of 3

Annual Journal Metrics

  • Citation Impact 2023
    Journal Impact Factor: 2.8
    5-year Journal Impact Factor: 2.8
    Source Normalized Impact per Paper (SNIP): 0.774
    SCImago Journal Rank (SJR): 0.710

    Speed 2023
    Submission to first editorial decision (median days): 25
    Submission to acceptance (median days): 178

    Usage 2023
    Downloads: 790,731
    Altmetric mentions: 400

Peer-review Terminology

  • The following summary describes the peer review process for this journal:

    Identity transparency: Single anonymized

    Reviewer interacts with: Editor

    Review information published: Review reports. Reviewer Identities reviewer opt in. Author/reviewer communication

    More information is available here

Sign up for article alerts and news from this journal